Smartlens, Inc. is a platform company aiming to prevent blindness due to Glaucoma and address the biggest challenges in Glaucoma management.
Smartlens' flagship product miLens is the first device capable of measuring IOP anywhere, at any time. miLens is similar to a daily contact lens and will significantly improve Glaucoma management as a non invasive, electronics free, ultra sensitive, and easy to use device.
Smartlens' THERmic applies microdose personalized treatments based on the patient’s diurnal IOP. THERmic can work with all types of Glaucoma medications. Smartlens owns a broad portfolio of clinical stage technologies that will improve Glaucoma management.
As the leading cause of irreversible blindness worldwide, Glaucoma (a.k.a. silent thief of sight) is a group of eye diseases that are very difficult to diagnose, treat, and monitor. More than 50% of the people suffering from Glaucoma are undiagnosed. Patients who are already diagnosed and comply with the treatment get their IOP measured at the clinic once every 3-4 months.
Our solutions will significantly improve patient outcomes and how doctors manage the disease by providing an efficient and convenient way of IOP monitoring and personalized treatments. With its strong IP, Smartlens has the unique opportunity to intervene and prevent Glaucoma-related blindness.
We envision a world where Glaucoma can’t rob people of their vision and quality of life.